IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
IASLC Exclusive Webinar: Treatment of Lung Cancer: 2020 ASCO Highlights
July 31, 2020 | Virtual Event


This webinar will synthesize lung cancer research presented at the virtual ASCO meeting May 29-31, 2020.  It will address physicians need to keep abreast of current research and future trends to inform clinical practice.

Dr. Chandra Belani will moderate the program and lead the discussion and question and answer session following presentations by Taofeek Owonikoko, MD and Melissa Johnson, MD.  

Dr. Owonikoko will review Small Cell Lung Cancer (SCLC), locally advanced non-small cell lung cancer (NSCLC) and Mesothelioma.  Dr. Johnson will review metastatic NSCLC. 

At the end of the webinar, learners will be able to:

  1. Identify recent data impacting the overall management of lung cancer patients;
  2. Recognize new and evolving developments in standard treatment paradigms;
  3. Discuss the status of ongoing and future clinical trials.

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants
Speaker Disclosure Information
Melissa Johnson: Consultant: Achilles Therapeutics, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, EMD Serono, Roche/Genentech, GlaxoSmithKline, Gritstone Oncology, Incyte, Janssen, Lilly, Merck, Mirati Therapeutics, Novartis, Pfizer, Ribon Therapeutics, Sanofi, WindMIL Therapeutics - All payment made to the institution, not Dr. Johnson
Contracted/ Supported Research Grant: Abbvie, Acerta, Adaptimmune, Amgen, Array, Apexigen, AstraZeneca, Atreca, BeiGene, BerGenBio, Birdie/Seven and Eight Biopharmaceuticals, Boehringer Ingelheim, Calithera, Checkpoint Therapeutics, Corvus Pharmaceuticals, Cytmox, Daiichi Sankyo, Dynavax Technologies, Eli Lilly, EMD Serono, Roche/Genentech, Genmab, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Hengrui Therapeutics,  Immunocore, Incyte, Janssen, Merck, Mirati, Neovia Oncology, Novartis, OncoMed Pharmaceuticals, Pfizer, Regeneron, Sanofi, Shattuck Labs, Stem CentRx, Synadax, Takeda, Tarveda, University of Michigan, WindMIL Therapeutics, TCR2 Therapeutics, Arcus, Ribon Therapeutics, Rubius Therapeutics, Tmunity Therapeutics - All payment made to the institution, not Dr. Johnson 
Consultant (spouse): Otsuka

Taofeek OwonikokoAdvisory Board: Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics, Takeda, Seattle Genetics, Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly,  Amgen,  AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Heron Pharmaceutical, ARMO BioSciences, Merck, Bayer
Contracted/ Supported Research Grant: Novartis; Astellas Pharma, Bayer, StemCentRx, Regeneron, AstraZeneca/MedImmune,  Abbvie, G1 Therapeutics, Bristol-Myers, Corvus Pharmaceuticals, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck
Ownership/Stock interest: Cambium Oncology

Chandra Belani: Speaker’s Bureau: Genentech, Takeda